Profiles of patients with bipolar disorder who may benefit from lamotrigine therapy Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
alcohol, bipolar disorder, pregnancy, lamotrigine, overweight, relapses, obesity, epilepsy, rapid cycling
Main Article Content
Abstract
Mood stabilizers are medications primary used in bipolar disorders. Lamotrigine belongs to the latest generation of this group. Initially, it was mainly used to treat epilepsy (blocking ion channels). Its normothymic effect consists in preventing the recurrence of depression and mania, stabilizing rapid phase changes, and in acute episodes of illness it has an antidepressant effect.
Article Details
How to Cite
Dudek, D. (2024). Profiles of patients with bipolar disorder who may benefit from lamotrigine therapy. Medycyna Faktow (J EBM), 17(1(62), 146-151. https://doi.org/10.24292/01.MF.0124.23
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Rybakowski JK. Two generations of mood stabilizers. Int J Neuropsychopharmacol. 2007; 10: 709-11.
2. Zarate CA, Tohen M, Banov MD et al. Is clozapine a mood stabilizer? J Clin Psychiatry. 1995; 56: 108-12.
3. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59: 530-7.
4. Thase ME. Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol. 2006; 18(4): 1213-30.
5. Bond DJ, Noronha MM, Kauer-Sant’Anna M et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: A systematic review and meta-analysis. J Clin Psychiatry. 2008; 69: 1589-601.
6. Ghaemi SN, Rosenquist KJ, Ko JY et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004; 161(1): 163-5.
7. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194(1): 4-9.
8. Grunze H, Vieta E, Goodwin G et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorder: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010; 11: 81-109.
9. Rybakowski J. Farmakoterapia choroby afektywnej dwubiegunowej. In: Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2022: 93-127.
10. Oya K, Sakuma K, Esumi S et al. Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacol Rep. 2019; 39(3): 241-6.
11. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000; 61(11): 841-50. http://doi.org/10.4088/jcp.v61n1106.
12. McCandless F, Sladen C. Sexual health and women with bipolar disorders. J Adv Nurs. 2003; 44(1): 42-8.
13. Rybakowski J, Cubała W, Gałecki P et al. Rekomendacje Polskiego Towarzystwa Psychiatrycznego dotyczące leczenia zaburzeń afektywnych u kobiet w wieku rozrodczym. Część II: Choroba afektywna dwubiegunowa. Psychiatr Pol. 2019; 53: 263-76.
14. Campbell E, Kennedy F, Russell A et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85(9): 1029-34. http://doi.org/10.1136/jnnp-2013-306318.
15. Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006; 8(3): 289-93.
16. Kanner AM, Ribot R, Mazarati A. Bidirectional relations among common psychiatric and neurologic comorbidities and epilepsy: do they have an impact on the course of the seizure disorder? Epilepsia Open. 2018; 3: 210-9.
17. Dudek D, Siwek M, Grabski B. Zaburzenia psychiczne w neurologii. Termedia, Poznań 2009.
18. Kessing LV, Ziersen SC, Gerds T et al. Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy – A nation-wide population-based longitudinal study. J Affect Disord. 2022; 308: 369-74.
19. Vieta E, Ghorpade S, Biswas A et al. Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar I disorder: Meta- -analysis from four randomized, placebo-controlled maintenance studies. Eur Neuropsychopharmacol. 2024; 78: 81-92.
2. Zarate CA, Tohen M, Banov MD et al. Is clozapine a mood stabilizer? J Clin Psychiatry. 1995; 56: 108-12.
3. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59: 530-7.
4. Thase ME. Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol. 2006; 18(4): 1213-30.
5. Bond DJ, Noronha MM, Kauer-Sant’Anna M et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: A systematic review and meta-analysis. J Clin Psychiatry. 2008; 69: 1589-601.
6. Ghaemi SN, Rosenquist KJ, Ko JY et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004; 161(1): 163-5.
7. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194(1): 4-9.
8. Grunze H, Vieta E, Goodwin G et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorder: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010; 11: 81-109.
9. Rybakowski J. Farmakoterapia choroby afektywnej dwubiegunowej. In: Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2022: 93-127.
10. Oya K, Sakuma K, Esumi S et al. Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacol Rep. 2019; 39(3): 241-6.
11. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000; 61(11): 841-50. http://doi.org/10.4088/jcp.v61n1106.
12. McCandless F, Sladen C. Sexual health and women with bipolar disorders. J Adv Nurs. 2003; 44(1): 42-8.
13. Rybakowski J, Cubała W, Gałecki P et al. Rekomendacje Polskiego Towarzystwa Psychiatrycznego dotyczące leczenia zaburzeń afektywnych u kobiet w wieku rozrodczym. Część II: Choroba afektywna dwubiegunowa. Psychiatr Pol. 2019; 53: 263-76.
14. Campbell E, Kennedy F, Russell A et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85(9): 1029-34. http://doi.org/10.1136/jnnp-2013-306318.
15. Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006; 8(3): 289-93.
16. Kanner AM, Ribot R, Mazarati A. Bidirectional relations among common psychiatric and neurologic comorbidities and epilepsy: do they have an impact on the course of the seizure disorder? Epilepsia Open. 2018; 3: 210-9.
17. Dudek D, Siwek M, Grabski B. Zaburzenia psychiczne w neurologii. Termedia, Poznań 2009.
18. Kessing LV, Ziersen SC, Gerds T et al. Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy – A nation-wide population-based longitudinal study. J Affect Disord. 2022; 308: 369-74.
19. Vieta E, Ghorpade S, Biswas A et al. Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar I disorder: Meta- -analysis from four randomized, placebo-controlled maintenance studies. Eur Neuropsychopharmacol. 2024; 78: 81-92.